(Q50795971)

English

The effect of B cell depletion therapy on anti-TSH receptor antibodies and clinical outcome in glucocorticoid-refractory Graves' orbitopathy.

scientific article published on 11 May 2013

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/23320840

The effect of B cell depletion therapy on anti-TSH receptor antibodies and clinical outcome in glucocorticoid-refractory Graves' orbitopathy. (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/23320840

1 reference

based on heuristic

inferred from title

Anna L Mitchell

1

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/23320840

2

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/23320840

7

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/23320840

author name string

Margaret Morris

3

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/23320840

Kim Johnson

4

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/23320840

Christopher Neoh

5

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/23320840

A Jane Dickinson

6

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/23320840

Simon H S Pearce

8

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/23320840

publication date

11 May 2013

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/23320840

Clinical Endocrinology

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/23320840

79

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/23320840

3

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/23320840

437-442

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/23320840

Clinical practice. Graves' ophthalmopathy

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12141

21 January 2018

Clinical practice. Graves' disease

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12141

21 January 2018

Graves' ophthalmopathy

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12141

21 January 2018

Pathogenesis of Graves' orbitopathy: a 2010 update.

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12141

21 January 2018

Long-term effects of Graves' ophthalmopathy on health-related quality of life

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12141

21 January 2018

Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy.

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12141

21 January 2018

Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of Graves' orbitopathy

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12141

21 January 2018

Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12141

21 January 2018

Rituximab for thyroid eye disease

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12141

21 January 2018

Rituximab treatment in patients with active Graves' orbitopathy: effects on proinflammatory and humoral immune reactions.

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12141

21 January 2018

Rituximab in relapsing Graves' disease, a phase II study.

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12141

21 January 2018

Treatment of Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies.

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12141

21 January 2018

Evidence for an effect of antithyroid drugs on the natural history of Graves' disease

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12141

21 January 2018

Efficacy and Safety of Three Different Cumulative Doses of Intravenous Methylprednisolone for Moderate to Severe and Active Graves' Orbitopathy

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12141

21 January 2018

Identifiers

10.1111/CEN.12141

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/23320840

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/23320840

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50795971&oldid=1236494625"